Lineage Cell Therapeutics, Inc. (LCTX)
1.09
+0.01
(+0.93%)
USD |
NYAM |
Sep 08, 16:00
1.10
+0.01
(+0.92%)
Pre-Market: 09:15
Lineage Cell Therapeutics Enterprise Value : 226.02M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 226.02M |
| September 04, 2026 | 223.49M |
| September 03, 2026 | 228.55M |
| September 02, 2026 | 231.08M |
| September 01, 2026 | 223.49M |
| August 31, 2026 | 228.55M |
| August 28, 2026 | 231.08M |
| August 27, 2026 | 243.72M |
| August 26, 2026 | 233.61M |
| August 25, 2026 | 236.14M |
| August 24, 2026 | 226.02M |
| August 21, 2026 | 223.49M |
| August 20, 2026 | 223.49M |
| August 19, 2026 | 228.55M |
| August 18, 2026 | 218.43M |
| August 17, 2026 | 218.43M |
| August 14, 2026 | 220.96M |
| August 13, 2026 | 218.43M |
| August 12, 2026 | 228.55M |
| August 11, 2026 | 233.61M |
| August 10, 2026 | 236.14M |
| August 07, 2026 | 228.55M |
| August 06, 2026 | 236.14M |
| August 05, 2026 | 238.67M |
| August 04, 2026 | 233.61M |
| Date | Value |
|---|---|
| August 03, 2026 | 231.08M |
| July 31, 2026 | 223.49M |
| July 30, 2026 | 231.08M |
| July 29, 2026 | 218.43M |
| July 28, 2026 | 220.96M |
| July 27, 2026 | 210.85M |
| July 24, 2026 | 210.85M |
| July 23, 2026 | 220.96M |
| July 22, 2026 | 231.08M |
| July 21, 2026 | 238.67M |
| July 20, 2026 | 228.55M |
| July 17, 2026 | 243.72M |
| July 16, 2026 | 246.25M |
| July 15, 2026 | 258.90M |
| July 14, 2026 | 258.90M |
| July 13, 2026 | 256.37M |
| July 10, 2026 | 274.07M |
| July 09, 2026 | 276.60M |
| July 08, 2026 | 289.25M |
| July 07, 2026 | 284.19M |
| July 06, 2026 | 286.72M |
| July 02, 2026 | 291.78M |
| July 01, 2026 | 279.13M |
| June 30, 2026 | 281.66M |
| June 29, 2026 | 284.39M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 581.29M |
| Amgen, Inc. | 255.86B |
| Anika Therapeutics, Inc. | 268.42M |
| BioCryst Pharmaceuticals, Inc. | 2.798B |
| Imunon, Inc. | 8.166M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.544M |
| Revenue (Quarterly) | 1.069M |
| Total Expenses (Quarterly) | -0.413M |
| EPS Diluted (Quarterly) | -0.0304 |
| Gross Profit Margin (Quarterly) | 82.51% |
| Earnings Yield | -16.91% |
| Normalized Earnings Yield | -12.70 |